Viatris Research and Development Expenses 2010-2025 | VTRS

Viatris research and development expenses for the twelve months ending March 31, 2025 were $831M, a 1.09% increase year-over-year.

  • Viatris annual research and development expenses for 2024 were $0.809B, a 0.43% increase from 2023.
  • Viatris annual research and development expenses for 2023 were $0.805B, a 21.59% increase from 2022.
  • Viatris annual research and development expenses for 2022 were $0.662B, a 2.76% decline from 2021.

Viatris Research and Development Expenses 2010-2025 | VTRS

  • Viatris annual research and development expenses for 2024 were $0.809B, a 0.43% increase from 2023.
  • Viatris annual research and development expenses for 2023 were $0.805B, a 21.59% increase from 2022.
  • Viatris annual research and development expenses for 2022 were $0.662B, a 2.76% decline from 2021.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$133.5B
Elevance Health (ELV)$96.1B
CVS Health (CVS)$84.8B
Cencora (COR)$55.6B
DiDi Global (DIDIY)$20.3B
Natera (NTRA)$20B
BioMerieux (BMXMF)$15.6B
Solventum (SOLV)$11.5B
ICON (ICLR)$11.3B
EUROFINS SCIENT (ERFSF)$11.1B
Revvity (RVTY)$11B
CochLear (CHEOY)$10.9B
Avantor (AVTR)$10.3B
Doximity (DOCS)$9.9B
Medpace Holdings (MEDP)$9B
Sonic Healthcare (SKHHY)$7.7B
HealthEquity (HQY)$7.3B
Charles River Laboratories (CRL)$5.2B
Amplifon S.p.A (AMFPF)$4.3B
Bausch + Lomb (BLCO)$4.3B
Alignment Healthcare (ALHC)$3.5B
Sotera Health (SHC)$3B
BrightSpring Health Services (BTSG)$2.9B
Organon (OGN)$2.9B
Surgery Partners (SGRY)$2.7B
GeneDx Holdings (WGS)$2.7B
Concentras Parent (CON)$2.6B
Progyny (PGNY)$1.8B
Ardent Health Partners (ARDT)$1.8B
Premier (PINC)$1.8B